Iloprost added to the cardioplegic solutions improves myocardial performance

Prostaglandins and Other Lipid Mediators

Volumn 55, Issue 1, 1998, Pages 51-65

  Katircioglu, S Fehmi ^a   Saritaş, Zülfikar ^a   Ulus, A Tulga ^a   Yamak, Birol ^a   Yücel, Dogan ^a   Ayaz, Selime ^a  

^a NONE

Author keywords

Iloprost; Ischemia reperfusion injury; Myocardial performance

Indexed keywords

CARDIOPLEGIC AGENT; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ILOPROST; INTERCELLULAR ADHESION MOLECULE 1; PADGEM PROTEIN; PROSTACYCLIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; CARDIOPLEGIA; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DOG; DRUG EFFECT; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REPERFUSION; HEART OUTPUT; HEART PERFORMANCE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; NONHUMAN;

ADENOSINE DIPHOSPHATE; ANIMALS; CARDIOPLEGIC SOLUTIONS; DOGS; HEMODYNAMIC PROCESSES; ILOPROST; MYOCARDIAL CONTRACTION; MYOCARDIUM; P-SELECTIN; PLATELET AGGREGATION INHIBITORS; TUMOR NECROSIS FACTOR-ALPHA; VASODILATOR AGENTS;

EID: 0031659084     PISSN: 00906980     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-6980(98)00006-9     Document Type: Article

References (57)

1. Zimmer S.D., Ugurbil K., Michurski S.P., et al. Alterations in oxidative function and respiratory regulation in the post-ischemic myocardium. J. Biol. Chem. 264:1989;12402-12411.
2. Nomoto K.I., Mori N., Miyamoto J., Shoji T., Nakamura K. Relationship between sarcolemmal damage and appearance of amorphous matrix densities in mitochondria following occlusion of coronary artery in rats. Exp. Mol. Pathol. 51:1989;231-242.
3. Kloner R.A., Rude R.E., Carlson N., Maroko P.R., DeBoer L.W.V., Braunwald E. Ultrastructural evidence of microvascular damage and myocardial cell injury after coronary occlusion Which comes first? Circulation. 62:1980;945-952.
4. Taylor I.M., Shaikh N.A., Downar E. Ultrastructural changes of ische-mic injury due to coronary artery occlusion in the porcine heart. J. Mol. Cell Cardiol. 16:1984;79-94.
5. Ferrero M.E., Marni A., Parise M., Salari P.C., Gaja G. Protection of rat heart from damage due to ischemia-reperfusion during procurement and grafting by defibrotide. Transplantation. 52:1991;611-615.
6. Katircioglu S.F., Küçükaksu D.S., Bozdayi M., Taģdemir O., Bayazit K. Beneficial effects of prostacyclin treatment on reperfusion of the myocardium. Cardiovasc. Surg. 3:1995;405-408.
7. Lupinetti F.M., Starnes V.A., Laws K.A., Collins J.C., Hammon J.W. Prostacyclin reduction of regional ischemic injury in the canine myocardium. J. Surg. Res. 41:1986;146-157.
8. Ganz W., Tamura K., Marcus H.S., et al. Measurement of coronary sinus blood flow by continous thermodilution in man. Circulation. 44:1971;181-195.
9. Wasowicz W., Neve J., Peretz A. Optimized steps in fluorometric determination of thiobarbituric acid-reactive substances in serum Importance of extraction pH and influence of sample preservation and storage . Clin. Chem. 39:1993;2522-2526.
10. Wayner D.D.M., Burton G.W., Ingold K.U., Barclay L.R.C., Locke S.J. The relative contributions of vitamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma. Biochim. Biophys. Acta. 924:1987;408-419.
11. Mankad P.S., Chester A.H., Yacoub M.H. Ischemic endothelial dysfunction after single or multidose cardioplegia. Eur. Heart J. 13:1992;976-980.
12. Selke F.W., Shafique T., Johnson R.G., Dai H.B., Barnitt P.F., Schoen F.J., Weintraub R.M. Blood and albumin cardioplegia preserve endothelium-dependent microvascular responses. Ann. Thorac. Surg. 55:1993;977-985.
13. Schrader J. Mechanisms of ischemic injury in the heart. Basic Res. Cardiol. 80:(Suppl. 2):1985;135-139.
14. Harjula A., Mattila S., Mattila I., Harkonen M., Myllarniemi H., Nickels J., Merikallio. Coronary endothelial damage after crystalloid cardioplegia. J. Cardiovasc. Surg. 25:1984;147-152.
15. Bolli R. Oxygen-derived free radicals and postischemic myocardial dysfunction ("stunned myocardium"). J. Am. Coll. Cardiol. 12:1988;239-249.
16. Braunwald E., Kloner R.A. Myocardial reperfusion A double edged sword . J. Clin. Invest. 76:1985;1713-1719.
17. Smith E.E., Naftel D.C., Blackstone E.H., Kirklin J.W. Microvascular permeability after cardiopulmonary bypass An experimental study . J. Thorac. Cardiovasc. Surg. 94:1987;225-233.
18. Rinder C.S., Bonan J.L., Rinder H.M., Mathew J., Hines R., Smith B.R. Cardiopulmonaary bypass induces leukocyyte-platelet adhesion. Blood. 799:1992;1201-1205.
19. Lucchesi B.R. Modulation of leukocyte-mediated myocardial reperfusion injury. Annu. Rev. Physiol. 52:1990;561-576.
20. Romson J.L., Hook B.G., Kunkel S.L., Abrams G.D., Schork M.A., Lucchesi B.R. Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation. 67:1983;1016-1023.
21. Simpson P.J., Todd R.F., Fantone J.C., Michelson J.K., Griffin J.D., Lucchesi B.R. Reduction of experimental canine myocardial reperfusion injury by a monoclonal antibody (anti-Mol, anti-CD11b) that inhibits leukocyt adhesion. J. Clin. Invest. 81:1988;24-619.
22. Smith J.V. Molecular determinations of neutrophil adhesion. Am. J. Respir. Cell. Mol. Biol. 2:1990;487-489.
23. Tonneson, M.G. Neutrophil-endothelial cell interaction: Mechanisms of neutrophil adherence to vascular endothelium. J. Invest. Dermatol. 93:53, 1989S-58S.
24. Forman, M.B., Virmani, R., and Puett, D.W. Mechanisms and therapy of myocardial reperfusion injury. Circulation 81(Suppl. IV):IV-69-IV-78, 1990.
25. Aoki N., Siegfried M., Lefer A.M. Anti-EDRF effect of TNF in isolated perfused cat carotid arteries. Am. J. Physiol. 256:1989;H1509-H1512.
26. Rosenbaum D., Levitsky S., Silverman N., Kohler J., Lipowski J., LeBreton B.A., Feinberg H. Cardioplegia does not prevent reperfusion injury induced by intracoronary platelet deposition. Circulation. 68:(Suppl. II):1983;102-106.
27. Hattori R., Hamilton K.K., McEver R.P.P., Sims P.J. Complement proteins C5b-9 induce secretion of high moleculer weight multimers of endothelial von Willebrand factor and translocation of granule membrane protein GMP-140 to the cell surface. J. Biol. Chem. 264:1989;9053-9060.
28. Lawrence M.B., Springer T.A. Leukocytes roll on a selectin at physiologic flow rates Distinction from and prerequisite for adhesion through integrins . Cell. 65:1991;859-873.
29. Bevilaacqua M.P., Pober J.S., Mendrick D.L., et al. Identification of an inducible endothelial-leukocyte adhesion molecule. Proc. Natl. Acad. Sci. USA. 84:1987;9238-9242.
30. Palluy O., Morliere L., Griss J.C., et al. Hypoxia/reoxygenation stimulated endothelium to promote neutrophil adhesion. Free Rad. Biol. Med. 13:1992;21-30.
31. Furchgott R.F., Vanhouttte P.M. Endothelium-derived relaxing and contracting factor. FASEB J. 3:1989;2007-2018.
32. Lange R., Ingwall J., Hale S.L., Aiken K.J., Braunwald E., Kloner R.A. Preservation of high-energy phosphates by verapamil in reperfused myocardium. Circulation. 70:1984;734-741.
33. Mullane K.M., Kraemer R., Smith B. Myeloperoxidase activity as a quantitative assessment of neutrophil infiltration into ischemic myocardium. J. Pharmacol. Methods. 14:1985;157-167.
34. Serhan N.A., Radin J.E.S., Korchaak H., Samuelsson B., Weissmann G. Leukotriene B4 is a complete secretagogue in human neutrophils. Bioochem. Biophys. Res. Commun. 107:1986;1006-1012.
35. Ytrehus K., Myklebust R., Mjost O.D. Influence of oxygen radicals generated by xanthine oxidase in the isolated perfused rat heart. Cardiovasc. Res. 20:1986;597-603.
36. Hess M.L., Eaton N.H., Manson N.H. Hydrogen peroxide and hydroxyl radical mediation of activated neutrophil induced canine mechanical dysfunction. J. Mol. Cell Cardiol. 18:(Suppl. 1):1986;70.
37. Taşdemir O., Katircioglu S.F., Küçükaksu D.S., et al. Warm blood cardioplegia Ultrastructural and hemoddynamic study . Ann. Thorac. Surg. 56:1993;305-311.
38. Deaton D.W., Pasque M.K., Pelton G.L., Freedman B.M., Cumie W.D., Wechsler A.S. Verapamil nifedipine and diltiazem. Comparative effects on ischemic contracture. Surg. Forum. 35:1984;303-305.
39. Krukenkamp I.B., Silverman N.A., Levitsky S. The effect of cardioplegic oxygenation on the correlation between the linearized Frank-Sterling relationship and myocardial energetics in the ejecting post ischemic heart. Circulation. 76:(pt 5):1987;V122-V128.
40. Kanter K.R., Glower D.D., Schaff H.V., Gardner T.J. Mechanism of defective oxygen extraction following global ischemia. J. Surg. Res. 30:1981;482-488.
41. Pober J.S., Cotran R.S. Cytokines and endothelial cell biology. Physiol. Rev. 70:1990;427-451.
42. De Mey J.G., Vanhoutte P.M. Heterogenous behavior of the canine arterial and venous wall Importance of the endothelium . Circ. Res. 51:1982;439-447.
43. Aiken J.W., Gorman R.R., Shebuski R.J. Prevention of blockage of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins. 17:1979;483-494.
44. Katircioglu S.F., Saritaş Z., Yücel D., Bayazit M., Taşdemir O., Bayazit K. Spinal cord protection with the use of prostacyclin during aortic occlusion. J. Surg. Res. 65:1996;77-81.
45. Judgett, B.F., Hutchins, G.M., Bulkley, B.H., and Becker, L.C. Infarct size reduction by prostacyclin after coronary occlusion in conscious dogs. Clin. Res. 27:177, 1979A.
46. Riberio L.G.T., Brandon T.A., Hopkins D.G., Redoto L.A., et al. Prostacyclin in experimental myocardial isschemia Effects on hemodynamic regional myocardial blood flow, infarct size and mortality . Am. J. Cardiol. 47:1981;835-840.
47. Ohlendorf R., Perzborn E., Schrör K. Prevention of infarction induced decrease in circulating platelet count by prostacyclin. Thromb. Res. 19:1980;447-453.
48. Katircioglu S.F., Küçükaksu D.S., Küplülü S., et al. Effects of prostacyclin on spinal cord ischemia An experimental study . Surgery. 114:1993;36-39.
49. Katircioglu S.F., Gökçe P., Özgencil E., et al. Prostacyclin usage for spinal cord protection during experimental thoracic aortic cross claamping. Vasc. Surg. 30:1996;97-101.
50. Lefer A.M., Ogletree M.N.L., Smith J.B., Silver M.J., Nicolaou K.C., Barnette W.E., Gasic G.P. Prostacyclin A potentially valuable agent for preserving myocardial tissue in acute myocardial ischaemia . Science. 200:1978;52-54.
51. 2 modulation of superoxide production by human neutrophils. Biochem. Biophys. Res. Commun. 113:1983;506-512.
52. Blackwell G.J., Radomski M., Vargas J.R., Moncada S. Prostacyclin prolongs viability of washed human platelets. Biochim. Biophys. Acta. 718:1982;60-65.
53. Katircioglu S.F., Küçükaksu D.S., Bozdayi M., et al. Effects of prostacyclin on heparin reversal with protamine. Vasc. Surg. 26:1992;464-471.
54. Schoror K., Ohlendorf R., Darius H. Beneficial effects of a new carbacyclin derivative, ZK 36374 in acute myocardial ischemia. J. Pharmacol. Exp. Ther. 219:1981;243-249.
55. Schror K., Funke K. Prostaglandins and myocardial noradrenaline overflow after sympathetic nerve stimulation during ischemia and reperfusion. J. Cardiovasc. Pharmacol. 7:(Suppl. 5):1985;s50-s54.
56. Smith E.F., Kloster G., Stocklin G., Schror K. Effect of iloprost (ZK 36374) on membrane integrity in ischemic rabbit hearts. Biomed. Biochem. Acta. 43:1984;s155-s158.
57. Van der Giessen W.J., Schoutsen B., Tijssen J.G.P., Verdouw P.D. Iloprost (ZK 36374) enhances recovery of regional myocardial function during reperfusion after coronary artery occlusion in the pig. Br. J. Pharmacol. 87:1986;23-27.